ImmunityBio recently released its 10-Q report. ImmunityBio, Inc. is a San Diego-based biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. Its lead product, ANKTIVA, is an FDA-approved immunotherapy used with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors, and the company also has programs involving cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The company says the discussion is based on its condensed consolidated financial statements and includes forward-looking statements tied to commercialization, regulation, financing, manufacturing, and clinical development. ImmunityBio specifically flags its ability to commercialize ANKTIVA globally in current and future approved indications, including NMIBC and NSCLC, and to seek additional approvals for BCG-unresponsive NMIBC with CIS, papillary-only NMIBC, and NSCLC.
It also highlights its dependence on additional financing to fund operations and advance commercialization and development. Other stated risks include compliance with the RIPA and related transaction documents, forecasting operating results amid fluctuations in warrant, derivative, and fair value measurements, and the timing and outcome of clinical trials, regulatory filings, and agency responses.
The company says it is pursuing ANKTIVA development across multiple tumor types and is relying on clinical data from Phase 1/2 aNK, haNK, taNK, and NK-CAR trials to support product candidates including NK-CAR (t-haNK), MSC, and M-ceNK. It also points to plans for international clinical, regulatory, and commercial arrangements, along with efforts to expand manufacturing, distribution, and in-house production capacity.
On the business side, ImmunityBio says its Cancer BioShield platform is built around ANKTIVA, a first-in-class IL-15 receptor superagonist antibody-cytokine fusion protein intended to stimulate NK cells, cytotoxic T cells, and memory T cells. The company says ANKTIVA is approved or authorized in five regulatory jurisdictions and is available in 34 countries for BCG-unresponsive NMIBC with CIS, with or without papillary tumors.
ImmunityBio also says ANKTIVA received accelerated conditional approval from Saudi Arabia’s SFDA in combination with checkpoint therapy for metastatic NSCLC after progression on standard-of-care therapy. In May 2026, the company said the FDA accepted for review its supplemental BLA for ANKTIVA with BCG in BCG-unresponsive NMIBC with papillary tumors without CIS, with a PDUFA target date of January 6, 2027. In July 2026, it said the UAE’s EDE granted marketing authorization for ANKTIVA in NMIBC with and without CIS, and for ANKTIVA with checkpoint inhibitors in metastatic NSCLC.
The company says it is also pursuing ANKTIVA in combination with standard-of-care therapies across BCG-naïve NMIBC, second-line and first-line NSCLC, glioblastoma, indolent non-Hodgkin lymphoma including Waldenström macroglobulinemia, pancreatic cancer, prostate cancer, ovarian cancer, multiple myeloma, hepatocellular carcinoma, and triple-negative breast cancer. It adds that the National Cancer Institute selected ANKTIVA for a cancer prevention study in patients with Lynch syndrome, and that it is supporting an expanded access program for rBCG to address U.S. supply constraints. Following these announcements, the company's shares moved -4.41%, and are now trading at a price of $6.835. If you want to know more, read the company's complete 10-Q report here.
